Absolute Benefit for Adjuvant Chemotherapy in Early Breast Cancer

  • Data from the Early Breast Cancer Trialists’ Collaborative Group:
    • Meta-analysis of adjuvant systemic therapy trials begun in or before 1995:
      • Show a 30% relative reduction:
        • In breast cancer-related mortality:
          • Associated with adjuvant hormonal therapy and with adjuvant chemotherapy
    • Reduced ratesof:
      • Ipsilateral local recurrence, contralateral cancers, and distant metastases in treated patients:
        • Suggest there is eradication of occult residual disease in many patients
    • The absolute survival benefit of adjuvant therapy:
      • Is greater in node-positive than in node-negative patients
    • The absolute survival benefit of chemotherapy:
      • Is greater for younger (less than 50 years of age) than for older women (50 to 69 years of age)
  • References:
    • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
    • Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.

#Arrangoiz #BreastCancer #CancerSurgeon #SurgicalOncologist #Cancer #BreastSurgeon #BreastExpert

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s